Lymphoproliferative disease after renal transplantation in Australia and New Zealand

Transplantation

Volumn 80, Issue 2, 2005, Pages 193-197

  Faull, Randall J ^a,b   Hollett, Peter ^c   McDonald, Stephen P ^b,d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c NAMBOUR GENERAL HOSPITAL   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Australia and New Zealand Dialysis and Transplant Registry Registry; Cancer; Lymphoma; Posttransplant lymphoproliferative disorder; Renal transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; AUSTRALIA; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AUSTRALIA; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEW ZEALAND; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RENAL REPLACEMENT THERAPY; REOPERATION; RETROSPECTIVE STUDIES;

EID: 23044483855     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000165098.49658.F3     Document Type: Review

References (18)

1. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154(6 pt 1): 1712.
2. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14(2): 214.
3. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10(6): 877.
4. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342 (8886-8887): 1514.
5. Cockfield SM, Preiksaitis JK, Jewell LD, et al. Post-transplant lymphoproliferative disorder in renal allograft recipients: Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56(1): 88.
6. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996; 2(1): 52.
7. Agraharkar ML, Cinclair RD, Kuo YF, et al. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004; 66(1): 383.
8. Chapman J, Webster AC. Cancer report. In: Russ GR, ed. The twenty-fifth report of the Australian and New Zealand Dialysis and Transplant Registry. Adelaide, ANZDATA Registry 2002, p 84.
9. Weissmann DJ, Ferry JA, Harris NL, et al. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103(6): 748.
10. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97(1): 14.
11. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995; 13(4): 961.
12. McDonald SP, Russ GR, Collins J, et al. ESRD in Australia and New Zealand at the end of the millennium: A report from the ANZDATA Registry. Am J Kidney Dis 2002; 40(6): 1122.
13. Hosmer D, Lemeshow S. Applied survival analysis. New York, John Wiley & Sons 1999.
14. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4(2): 222.
15. Shapiro R, Scantlebury VP, Jordan ML, et al. FK506 in pediatric kidney transplantation: Primary and rescue experience. Pediatr Nephrol 1995; 9(suppl): S43.
16. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20(5): 1346.
17. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329(14): 987.
18. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): Prevention and treatment. Nephrol Dial Transplant 2002; 17(suppl 4): 31.